ELTP - Earnings call transcript Q4 2019 | Elite Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen and welcome to Elite Pharmaceuticals Conference Call. At this time, all lines have been placed on listen-only mode.

Before management begins, the Company has the following statements.

This conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to the effects, if any, on future results, performance or any other expectations that may have some correlation to the subject matter of this conference call.

Listeners are cautioned that such forward-looking statements involve risks and uncertainties including, without limitations, Elite's ability to obtain FDA approval of the transfers of the ANDAs or the timings of such approval processes, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements.

a include all, the FDA, the of Elite take may approval, timing the FDA statements CRL, of may at the the in if SequestOx as obtain require forward-looking of statements actions order expected regarding of steps and Elite These the of to of approval result by the NDA. require statements SequestOx of of approval, actions all, of by These obtain FDA the timing the in approval forward-looking if NDA. Elite expected FDA statements order to regarding the may the the include and of at

and Exchange future alter These Food on factors, of forward-looking other and future statements in is future intellectual statements, with or and action discussed information, ability under are and the or X-K. regulatory limitation, from or and obligation filings trials, the without clinical Agreement, These not under as a to other protections whether timing and guarantees other and LPC of otherwise. including sufficient forward-looking new are approvals the events by funding defenses, of Elite Drug the no Commission, to results property risks and regulatory pending or Elite's reviews, obtain performance. Administration including or XX-K, XX-Q, authorities update Securities its its and Elite's result Forms reports sources,

Officer over With that Executive covered, Pharmaceuticals. floor host, Elite your to floor Nasrat to now Mr. President my the it is Chief of is Sir, turn Hakim, and pleasure yours. the

Nasrat Hakim

then a update. ladies Carter to we'll Dianne. have with go Elite's call. will going get would earning and already to Good you go of Carter Paul. that to corporate then morning, first, financials submitted follow Usually, questions you, you gentlemen, and couple I'm first, welcome have and Thank back Today, through I give

listed Elite going Even aware, in of late are what's notification I to an it filed or am ago. is perspective. though with and an given two the unusual you a event, paraphrase SEC a added week the you K not filing As

an unusual filing Delay in or companies. traded publicly requesting among event is not extension an

reporting have file not In the fact. companies where to all Elite. a financials, delay were was That our and fact, used restatements we fashion, SEC specific issue. timely after for was ready heard with warnings the to issue in instances not but issue. the a is The auditor's which Elite's rather not related pleased on report in case attorney way of the at Ks another

So he asked an for explanation.

that audit because used to that documents issue associated stated of enough documents audit wording with filed allow an auditor them with the that financials. ensure extension provide the have to the they did section. The Elite's and to requested them, assessment accurate time not to time they auditors We thoroughly such they enough the

issues material of Material don’t internal weakness of two our we of balances auditors all in transactions. enough some is controls checks of two, and identified weakness in One have controls and that on the the is that, internal Regardless concern. going concern. means

DEA and rules of which for. audit must by FDA that means FDA rules, by every governed be piece are We them. inventory and accounted DEA

means whenever pharmaceutical so manufacturing life easy. being a into waste, DEA What controlled product, kilos on stability, audit buy that auditors' industry very to was the that of what What wants a a trail XXX what regulated nice went where went. a industry went as single is part we into put of that gram the a there is every makes very substance, in know the

such and that strictly are transactions receivables need However, well. and financial there other as audited be those to are payables as

and a Carter and him. checks our have position left he and the back while have balances replaced second-in-command to we Carter's We Elite that not on was

item going the second is concern. The

our at we is common and don't simplifying or which greater to am current run income a so. our company a I That for about means, that R&D statement. are our paraphrasing, and is, than enough for expenses concern rate an Going operate and have true year is money that

ANDA working with of our cost Our we capital, fees, for $X costs FDA products main product coupled are launches, we infrastructure GDUFA are. million, and limited the API are where facility fees reason commercial

position So working to The how sales our do it? and eliminate to is raising situation capital, for again. and having we launches, product to fix our long-term in short-term revenues fixed remedy cover be current money cost, increasing this and

this partners this to I our We very now problem have years ourselves we and one and ANDAs fixing that Creating close companies with line an by believe reach as sales such for few solving another. that have means up Glenmark overcome do, teaming we wider another, Generating new is infrastructure been much and working are is marketing product issue. will to than with on our Lannett it. is support and

with me start that. So let

distribution are marketing hoping them; good partner are Epic have launches and or modestly holding and product the achieved of Trimipramine, sales and and it. they partnership was that they will started recently Phendimetrazine, TAGI considerable have market a they Lannett. four Trimipramine, from Phendimetrazine, in just last transitioning Glenmark, marketing date. share place they we the Isradipine, met place Methadone, three process and Sales companies their to our for the and in and we Isradipine. year that improve Elite, maintain and now have partners to with them. in put targets our products we sales and and of today have that are it is have we Glenmark have old Methadone,

next this co-developed Amphetamine have tablets, last month the was Lannett, sales launched product first we the this with IR product and significant of the our expect we quarter. begin to and in year them; was partnership partner three products was a SunGen. in Lannett signed This quarter with

release The nervous central product. system an second extended is

second SunGen. This co-developed and not have do product under we product the the it our is it once approved. is This with partner We is so will and is disclosed yet with filed FDA review.

do the test and the Let We the filed status for in test without no have in for. the March dose we several can FDA of we perform we to if me for writing, need other pumping the you what that on that asked We system in through this extended asked this April We pause to and considering waiver waive a test. alcohol are correspondence, the approval we filing They preparation what patent to May. ANDA ANDA FDA nervous launch in filed go We central planned us dumping was guide product. already the that expired need called update GDUFA a The year. writing. ANDA release XXXX. a patent last at of there said this In product. the XXXX questions controlled on people point date to we and

an the us about up. During not the among by the or things They the application FDA, few requested prosecution injection review answered had other of elaboration come they explanations the practice asked and answer is The for on time typically of or this submitted did things, and site answered FDA. which the a it, to common clinical we question answer. it typically CRO common

was for assured shutdown. If will period were shutdown government we're the it it. government paying according that And got handled FDA the by reviews you'll not. during to review be recall, ANDA because this not We

that dose our have to requested the waived submitted CRO date, surprise pumping and injections go that time said did the the response our review enough they they on and GDUFA to on test we to FDA which that However, time. not alcohol were the back do

date GDUFA new our Now XXXX. is December

the we to why led to controls. or of replace more that our are me is tightening carry cetera, and viable we problem company have this with a action. the breakeven ramification we letting Let go did us profitable some employees we explain of This months. cost, others its Instead belt, infrastructure eight have not API internal which et becoming of and for the

was product we And when we concern, that questions launched supposed auditors. because from approved have that we May, if and is to it also approved the in going why was any wouldn’t be it have

Just quite under now are things with lot a need shifted, were planning for in and of to what the how do delay dealt bit here, we few up little Elite doing can of looking or right will delay that and ahead state on we example by a way are there get things be of circumstances. things still to I a

March look last from the earnings If our roughly quarter, earned ending we about quarter. at XXXX, quarter you during that million $X.X

that ending June this than quarter is ending ending as current the much in good I times and be current at will XXXX, should this three be quarter quarter. quarter as earnings will in that. quarter, for the double as as the quarter before twice March quarter be XXXX just larger expect in XXXX December Our The least the September

the system coming are up and it were quarter nervous lined partners, quarter it revenues June And the moving up. projections ending have up our already that things that from all lined ER sales game had central these we and quarter our after after, a So in and changer. to needle working will the we coming are mover with a them definitely been partners be and if would added

means, up, to something that infrastructure employees else of use for invested whereby is all pay you is we you money and and have the small detrimental a Now our cannot live carry company. we capital in tied in for and working our API really cannot

the way, test minds. go concern if changing told actually FDA this their have saying the a controls want us government of in that were waiving and could if going things into, of the it well time as could So instead yes if do shutdown, to as you certain hadn’t no we the then ahead dissipated went

They everybody, Again, small we we're this they against need practice. can with this That's take company standard this FDA. that do is This all companies a and and money the nothing the is the except time. not big can't. conspiracy, do the it a

because is this have come product biggest not relied case it did heavily for on something been through in and would this we that our However, us.

that December, and are independent of numbers the We through you that. hope gave I comes in

out the because to massive talking the would We way. I the to other in the am better the that hit FDA much only approve much when the make after, will company on quarter, waiting we better succeeded If focusing do the and about going predict and have of the making anti-abuse on it, ER and products XXXX approval company cake. not QX ART other a make. and changing are I be on at QX am they really of ART of difference really prediction from SequestOx for will in our viable quarter I opioids well XXXX. this abuse-resistant icing am about would to be we actually the That

Okay?

survive it. money communicated It high. very if is very Street order to to Raising we In money but with to raise with to had the expensive, and have do cost very dilutive investors we and least to multiple all experienced the Wall with, have that pursue. shares, dilutive is The banks all do Wall will options all through Of the have we we Street. have Capital expense. risky, met Lincoln for it method our we Park and least table, the us on we least is

this that discuss discussing in weeks, first when to so, in deal have all be that, stated will we or about that the Capital already need that team we is seven of This sales in we authorized meet Lincoln August Park will the team, we in again K why we In and XXth outstanding with. and addition to and is more additional depth. further class

our within reason we becoming presentation for us wanted continue sure happen moving them are again, independent, all nimble to does what control. that we the with with are what doing I change not modify before having factors with and come in my auditors summarize I to to fundamentals as goal for on. achieve and our up said plans and of existed and is, We in you ourselves order again can order to these move of things make financially it are what the So

we product Dantrolene have very that's for Lannett is approval five capsules, We've launching now had the with last product launch Okay transfer, a years, we're soon. site partner, signed a deal, a Epic that and and of made public be we assuming This that received for moving and deal it quantities transfer. will found back got site we signed weeks. couple a between done the and we forward have in October October a

controlled them of right Naltrexone, oldest fear nobody capsules. are had and They products they opioids tablets TAGI selling because the approaching by Phentermine with substances Phentermine is they three stopped it we and all lawsuits our hydromorphone marketing selling partner states are across country. now, nowadays, and because is the on going that have the that of

used even mean is really technology, is antidote and is to clinics habit. abuse anti-abuse. So in which Naltrexone, and methadone in with I methadone they are methadone get used ART is as we opioid have people it products, our also though selling kicked off used heavily three Naltrexone the help an not

I'm these products. have from cite and including approval we to methadone filings, we are ANDA IR all, and had all of Dantrolene them and not several approvals, commercializing going

afford. crisis and for to don’t On partner going the losses part and can't in to a now APAP are that not a and the states landscape opioid want Hydro the front, people of have APAP and opioids Oxy are on these reacting the to hydromorphone secured I'm hurry be are we not secure because partner and have we of the are have frankly because because we I opioids how reacting any and the they and opioid losses, and I

Okay?

see abuse ANDAs, sudden it to of all and head. all of over provides approval and because changed landscape system an hanging of GDUFAs the that done thinking that fear honorable got patients part for of the we are relief disheartening is work, it to paid lawsuits could we've this somebody a that our instead now needing created a hard and So pain

these we're sure the them So settles to find going I'm products dust future, the are the a way even though to for to market. once get

there are For not now yet. we

under we exactly and I stand. and described The is to where extended CNS you review peer what release ANDA just happened

December at they because We won't be because that a that be they didn't will the any and any they will have to delay time approved are it us. in more game and had look hoping ask questions really was and questions for changer definitely never it

we has probably APAP ANDA November, should in least codeine at sometime tablet and or a antibiotic year get of from in QX we with and Tylenol The approval get been filed and year filed hopefully it approval with this of QX codeine so response. we this should FDA in

Okay?

are proved will trial take I the and the the characterization did assessment TMX on repeating by you additional can and work a abuse with quickly and since without certain on we nothing intravenous clinical or came FDA with route [ph] product [ph] a start an the of happens that cost our SequestOx, for on a risk it hopefully focusing update money to has going getting will food, excipient changed we of company that back we'll we make larger of on this, and things and but that are that now profits scale, lot like the capital, spending hold. survival, for us on working we products viable that we for generating once start now know definitely and is

many Now is we focus. because to for having our development that, a also spending launch, they to to year half not money have day so we million the a gave for ask on again $X.X now down costing we're it so and we they any did it in need us and requested We money because and but change of all we and for waived and products the said us lot right it we obvious that good, slowed FDA extension that's of need the the meantime, from reasons.

not is huge. facility Our that

become our buildings, order all we're two to partners of these sure in here coming, be and cannot make marketing to have be trying that and with we and products satisfy running definitely a the We needs volumes company. for so selective are anything afford we partners and in us to but sales profitable

product the be and not, $X.X central products the product in product that. fees December. an can we shying IMS doesn't nervous small as products big filings that, that’s that but are going we that's all will from. said as, data putting big shy our we if resources this including to extended Having with that’s are The of works has away trying on, we’re few the system coming over very in from trials have and Any bigger billion is do clinical to that and viable much still any we money cost away one strong little than that we’re do, release function that and that work

this that sales section getting game stockholders of groups, whether auditors. an identified and investors up In stated the changer with increasing quarter, huge this for sales, teams. us December the were and in definitely all help wrap the I quarter could first our approval quarter, pending and FDA is by future, in that based for revenues see We is all this, to just expect the new as to that be to the sales the see two marketing generating so a we as Carter, in product and continuing, before Okay, ANDAs, it growth next issues solid us resolve increase the turn and over I getting really after. of on of employees. is we And in that's us, going the the potential

floor. Mr. the have Ward, you

Carter Ward

you today. ended Okay, everyone a year we're on thank calling for and March March Last XXXX, Nasrat, Friday year. XXst thanks XX, we XX-K fiscal filed the our in to fiscal

fiscal us. So website on to of XXXX elitepharma.com well for as that's provide the filings. our our links is K the websites other that investors is many The sections as SEC.gov which available and

please gone a sites. haven’t of the you or from usual get the if other K elitepharma.com any copy So yet, through

the by this me that two a add more. just start I’ll that but not K of gave K. items them, good were summary discussing little last Nasrat Let in a the in year's were really

going that, these had the happened weaknesses identified First time have The opinion we XXXX audit both year. fiscal the in concern qualification. And concern the of is weaknesses the internal before. last And so year, we second was item the including such is going of opinion material was a material the controls. had time fiscal last identification XXXX

give of I’ll the I already. context, read to a has careful and let’s controls controls, with XA On my detailed best procedures. area. really although a background you complex So item job that recommended provide summarize on good and it’s a call, a and K and internal start Nasrat the do did this in discussion some

tests designed only which are, what The and the what performs and tested also integrity controls, systems they are procedures they document are that them, they financial are and information. the are not are, also correctly, Internal who tests they controls in of accounting documented. and ensure operating they but evidenced. they are and These controls are to demonstrate the these are designed effectively results how to implemented of

prior years, the XXXX the both for and Now internal years and two resources had XXXX fiscal we and personnel external.

We also for they there external place and had significant were both and resources identified successfully were this. two We consultants, in controls took personnel them material but those tested. were sufficiently use no this, It years. to during do our documented, wise, weaknesses financial

year and During accountant, we who lost this certain XXXX, fiscal not personnel right testing man were replaced. controls specifically however, my performed senior and hand my

In external financial environment. constraints that maintain that to the addition existing able the resources, were and control had due were to to required consultants engage we the used not we

to to demonstrate two have when to redesign update personnel done your controls all to have the of reflect controls after are the to that working, things, test changes need and these So resources you the new they’re controls you you the the prove, and that first, working. second, that, happens documentation do and you've related in to

resources, and also anyway are that of time wasn't with existing implemented. the and revise were enough testing controls for personnel available they new there new While period the document allow controls to document time within any to had fully adequate been consistent not able controls and and we the

to - order have controls be to to something in to tested. these to has a chance They be have elapse test. to many time have of to for have Remember you performed

in in happened. results controls So an and identified - a material internal what that’s weakness that's

various In in were in now addition, this segregation did that when we many by was by I being much and some most staff also. This this material our a insufficient reconciliation of years ago reviews, and had cases weakness previously back balances an smaller done well also the duties the performed CFO checks of are others me, then work as weakness. results and material

however, while the issued that have financial unqualified material identified in internal weaknesses our note have I our we auditors will opinion on an statements controls, themselves.

So control despite auditors a concluded that audit, financial fairly that based say our themselves have that and thorough existence of the means thorough, weaknesses, would the is very number present I statements. what upon the

and even a section still get in are weaknesses noted a There and of the opinion. factor is away those this themselves if weakness. such risks numbers the nevertheless with are associated don’t risks But they clean even the risk K, go

the of So in have internal effective over controls, controls. we the demonstrate we are fix then design adequate to framework, time meet We effectively. need that’s meet order implement the them document and this standards to in the test set COSO need which criteria need now forth to controls. new We to to need operating to them to need that period they we an to

This for now. project task XXXX in a a big us us did remains big it for it was and when we first

control Additional remediation correlation these our weaknesses correlation, strong a direct a personnel timing internal and have of position. of financial are to the significant does resources so required, successful

Now what of to quite careful going Nasrat K reading going also there concern. well, our gave the opinion. operate some opinion context, as to auditors I'll well as recommend a a which than well. a my to Note financials in I disclosures try concern as the call And little are ability summarize, the this best of in more explained the as provide X to Nasrat

company an to which operate able being term, defined certain it's a year the audit the that's usually of concern, report. the one Going date for as relating period to beyond accounting is

statement of substantial Our to cash of cash to the losses that’s statement. flow outflow concern net on and of operating a disclosure operations the on going ability a our doubt due K of and a operating our as includes

as to therefore have concern, this through XXXX. resources statements and years. we XXXX stock did our notably concern financial sales not from common opinion We of in through going had however, additional From going those were have ensure to investment, for able due successfully we operate Lincoln opinions XXXX the to through a most from adequate XXXX Park

the place to stock not of months year, does this even operations Park line Lincoln the coming common level current equity however going XX sufficient level ensure to XXXX still a stock In our with Park to fix a as of very the gave price forecast Lincoln The of we’ve in sales concern. enable in at Nasrat detailed increase what as need a Elite. everyone new summarize, of gone the existing description we’re for bring and but also focus primary products, do, this additional to over, doing, sales really to our investment of in products is we reducing us expenses.

So on pipeline. products, Nasrat the gave update the an

as far cost gives there on related to As our annual information proxy additional shareholder an are and have efforts XB is and meeting investment additional which implemented continuously they regarding item in is which been K reductions monitored. the investment and

tightening belts We’re lately. our really

million product financials, year-to-year us prior but to end Naltrexone essentially and compared on a much for to through the was a up very a now product been $X.X flat million is it’s starting doing pretty XXXX that a XXXX little the as from fiscal different increase $X.X was as compared very for well. million year basis, for revenues $X.X today flat, and the this nice year the the fiscal mix So, last the of has from continuing to year year. over prior year, different, it’s

to the year, that's prior some fiscal fiscal generic through in and XXXX own there fiscal our Methadone is towards alliance so end being marketed compared of That's of happened no our Methadone partners. in Glenmark, also That the year year. one XXXX year, the products. We the contribution the in contribution also launched

the once marketing the no ordered side, this as opioid is been the reason or various placed On hydromorphone for us are was years and a opioids product by which longer partner yet states. being actively strong on additional the by litigation TAGI, is taxes also marketed in market not flip main explained which our have our which for prior for both this conditions, has there

during no XXXX these retroactive, which there for Some of so sales hydromorphone were us fiscal were the an taxes caused even year. and expense quite

Not to did XXXX revenues are reflected shipments immediate the alliance have of Adderall the one that of some we the our There of product in mentioned. fiscal partners. just Nasrat generic the things year not release of Lannett,

shipment The first XXXX. of first of the out products these April in week went

missed these March just well for to also Glenmark March and as and XX occurred cut first just XX other off. of shipments this Isradipine year, alliance we the off our cut not our fiscal the also after included So is partner Trimipramine

are these missed cut a are significant XXXX but just not currently the the making to off. So that the they are things cutoff fiscal K. in They subsequent March of year, the difference

of significant this during significant of in XXXX and market alliance partners, them but is year Glenmark represent marketing addition The minimal improvement as joint now Lannett with because it being they fiscal since our March from contribution timing reach the just XX.

Adderall, the immediate and the near especially which they expectations is which Sodium Lannett generic generic product very and optimistic, launch future. release is expected we’re So XXXX are March Dantrolene Adderall already exceeding about our alliance with with which in was Dantrium in of instituted

from year. the So to Lannett being There’s variance XX, and March prior wasn't much and mix summarize contribution and today. March of slightly to number there contribution after the different product just of operations, occurring are our prior wise, minimal results XX Glenmark growing from the cut and off a continuing mostly through

Now, question Mr. which this CEO, we’ll answer Nasrat part by Hakim. move be led call of and to the our will

Nasrat Hakim

Carter. you, Thank

Nasrat Hakim

I'll it sent, all FDA. fast through so to we consolidated as did in have not and and sent that went them Starting answered I what glance of possible. front already Dianne first have like as as try of at quite I've them did some I bunch Great, through me, answered go few. you papers several with the And a questions, of SequestOx details you she no I seems always the of and status do of with a

be in new cheaper platform or used Elite ADF NDA that's Is IR shown to document ANDA?

Nasrat Hakim

product, will that's least that a at our request FDA. generic be of ANDA

Q -

How with are this far we along product?

Nasrat Hakim

Well be down. to it's it we're going slowing an opioid, so

settled before We landscape we going to and need hat we have see ring. make are throw that because there with on into lawsuits trials what's the our begun sure clinical not the obviously the

ADF an the possible? is platform that of ADF is robust abuse chewing new IR How oral, is

Nasrat Hakim

Yes.

Adderall Dantrolene? why issue approval the Elite IR upon not of and Dantrolene, did press releases

Nasrat Hakim

This site is transfer. a

You a site for don’t transfer. issue press releases

IR they then Okay? for And quiet and date. them ship that's we different the Adderall any time for a material marketing they launch at receive that a material and our partner, not to sales because all launch

don’t gets send accurate information. to be messy want it really and we any So out to

do the So you usually is update we meeting when during and start what these that. we that on announce sales

site the of any transfer Have launched drugs yet?

Nasrat Hakim

launched of one Yes, Trimipramine launched and couple pending is with Loxapine next and definitely and and for Isradipine is as and it the answer them to weeks filed FDA well. Dantrolene us. waiting in approved The

Are changes strategy? any to relations going investor months. three for be the to there Elite's substantive last announcements Zero

Nasrat Hakim

to not are have or on stockholders announcements. and Our for worked I and announcements that companies are do. Street as many lot calls of they updates NASDAQ many have do and Wall a addicted as we as conference

stock company. We are a penny

think we what materialize our single personally on not We times are obligated I time we're not, the or you a take you the every can to company go FDA. even call, guys earnings four single filing doing. is this to what and on not call, are time vision earnings with do through are that. year, quarter things have of update they every whether I the do the That's update an that's pending that beyond we yet we status

whenever stock a company ask little to temper understand question a lot. expectation for a So getting are Okay? you your penny and a you and need

the Okay, the of status what extended is release? CNS

Nasrat Hakim

that us and what's date hoping thoroughly, you on be the with is going that this am GDUFA through if is when the and product to went was happened GDUFA the map will. when already FDA, the financial puts I really I date, new

Norco going Percocet and What on is generic? with

Nasrat Hakim

are are As launching to and narcotics these before, has I nervous anything with have now. stated about right partners many that really narcotics do

Tylenol Does have opioids? as with similar codeine the concerns

Nasrat Hakim

palatable been some less good which the it it, easier codeine part it doctors X to with X, a easier The and for to store us with of codeine lot for a not it schedule Tylenol extent. is it APAP them not a prescribe To yet. more that it. lawsuits lot makes for news schedule is a is for also or and And has potent it do to

to an So our all enough issues. we until to and resolve partner anybody approval, brave see if once we have is get at we'll we wait these be

Phase What Isradipine about trial? the X

Nasrat Hakim

for I what, the for and was day was settled has patients came would even the you, in the not or announcement regardless Elite can dust of successful, not. disappointed am of know I it you whether already that Chris on We'll, the now sake Dianne benefited the that coordinating for tell But very trials didn’t I because product Parkinson's have But the thing wonderful even clinical owners sponsors if would were to a meet been it we that money making news the the even Parkinson's. make not of and willing came the work. did and any of with with the to anybody we in have product or the actually help this

Paul. seven for Thank weeks. you This Thank much was and concludes very last call question to about the ladies our we this you, in talk and you gentlemen today. and will

Operator

does this gentlemen, and Ladies conclude you. today's conference Thank call.

phone at lines You your a you day. participation. this have Thank wonderful for and disconnect time may

Elite Pharmaceuticals (ELTP) 24 Jun 192019 Q4 Earnings call transcript